<DOC>
	<DOCNO>NCT00002976</DOCNO>
	<brief_summary>RATIONALE : Estrogen replacement therapy may improve quality-of-life postmenopausal woman endometrial cancer . It yet know whether estrogen replacement therapy affect cancer recurrence . PURPOSE : Randomized double-blinded phase III trial determine effectiveness estrogen replacement therapy treat woman stage I stage II endometrial cancer .</brief_summary>
	<brief_title>Estrogen Replacement Therapy Treating Women With Early-Stage Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect estrogen replacement therapy recurrence free overall survival woman history stage I II endometrial adenocarcinoma . OUTLINE : This randomize , double blind study . Patients stratify accord stage endometrial cancer ( IA vs IB/IC v II ) . Patients randomize one two treatment arm : - Arm I : Patients receive oral conjugate estrogen ( Premarin ) daily 3 year . - Arm II : Patients receive oral placebo daily 3 year . Patients follow every 6 month 3 year annually 2 year . PROJECTED ACCRUAL : Approximately 2,108 patient accrue study .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm grade I , II III endometrial adenocarcinoma ( endometrioid , villoglandular , mucinous , adenosquamous , papillary serous , clear cell , otherwise specify ) Must total hysterectomy bilateral salpingooophorectomy within past 20 week Surgical stage IA , IB , IC , IIA ( occult ) , IIB ( occult ) disease Must normal mammogram , negative breast biopsy abnormal mammogram , within past year PATIENT CHARACTERISTICS : Age : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal No acute liver disease Renal : Not specify Cardiovascular : No prior thromboembolic disease Other : No prior current carcinoma breast No prior invasive malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : No concurrent hormonal therapy Radiotherapy : Not specify Surgery : See Disease Characteristics Recovered prior surgery Other : No prior cancer treatment would preclude study therapy Concurrent participation GOG Lap1 GOG Lap2 allow</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>stage I endometrial carcinoma</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>endometrial adenocarcinoma</keyword>
</DOC>